Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-08-11

Opinion for Teva Pharmaceutical (TEVA-N)

Signal Price Bias Subject Owned
DON'T BUY $17.300 UNKNOWN GLOBAL EQUITIES & TECHNOLOGY No

A very complicated business. It is contractually driven. They build the company based on accumulating assets from institutional investors. The stock has been a fabulous performer. He thinks there is more upside.

Darren Sissons
Vice President and Partner, Campbell Lee & Ross

No Comments.


You must be logged in to comment.